Objective
Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.
Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.
Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences public health
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses ebola
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-POC - Proof of Concept Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2016-PoC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
171 77 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.